ClinicalTrials.gg
CompletedNCT05295940Updated Apr 1, 2024

A Study of LY3841136 in Healthy and Overweight Participants

A Phase 1 interventional study of LY3841136 and Placebo in Obesity and Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-01.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing eloralintide in Obesity — 14 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.

Enrollment
15th of 22
148 · median 315
Started
2022
the only one that year
Phase 1
9 of 22
4 open now
Registered
1st of 22
by date
Lead sponsor
22 of 22
Eli Lilly and Company

Among the 22 studies testing eloralintide in Obesity, this one is the 15th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 1, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

14 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About eloralintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing eloralintide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.

03

Conditions studied

  • Obesity
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who agree to use highly effective/effective methods of and female participants not of
  • Have had a stable weight for the last 3 months
  • Have a (BMI) in the range of 18.5 to 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of 27 to 40 kg/m², both inclusive (in Part B)

Exclusion criteria

Exclusion Criteria:

  • Are women who are lactating
  • Have known allergies to related compounds of LY3841136 or any components of the formulation
  • Have a history of significant atopy (severe or multiple allergic manifestations), or multiple or severe drug allergies, or severe posttreatment reactions
  • Have been diagnosed with Type 1 or Type 2 diabetes mellitus
  • Have a history of chronic medical conditions involving the heart, liver, or kidneys
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    LY3841136 (Part A)

    Single ascending doses of LY3841136 administered subcutaneously (SC).

    Drug: LY3841136

  • Experimental
    LY3841136 (Part B)

    Multiple ascending doses of LY3841136 administered SC.

    Drug: LY3841136

  • Placebo comparator
    Placebo (Part A)

    Placebo administered SC.

    Drug: Placebo

  • Placebo comparator
    Placebo (Part B)

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Predose up to 14 weeks (Part A) & 28 weeks (Part B)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136

    PK: AUC of LY3841136

    Time frame: Predose through week 14 (Part A) & week 28 (Part B)

  2. PK: Maximum Observed Concentration (Cmax) of LY3841136

    PK: Cmax of LY3841136

    Time frame: Predose through week 14 (Part A) & week 28 (Part B)

  3. Pharmacodynamics (PD): Change From Baseline in Body Weight

    PD: Change From Baseline in Body Weight

    Time frame: Predose through week 28

07

Study locations

3 sites
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jan 2024, 21 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 21 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2022
First posted
Mar 25, 2022
StartActual
Mar 30, 2022
Primary completionActual
Jan 25, 2024
CompletionActual
Jan 25, 2024
Last update
Apr 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05295940
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Mar 30, 2022
Primary completion
Jan 25, 2024
Completion
Jan 25, 2024
Last update
Apr 1, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eloralintide

Start the discussion